前十大流通股东累计持有： 15167.12万股，累计占流通股比： 29.85%，较上期变化： -991.29万股。 | 名称 | 持有数量(万股) | 占总股本比例(%) | 增减情况(万股) | | --- | --- | --- | --- | | 光正投资有限公司 | 12916.87 | 25.41 | 不变 | | KING JOIN GROUP LIMITED | 508.52 | 1.00 | 不变 | | 乌鲁木齐绿保能教育咨询有限公司 | 313.89 | 0.62 | 不变 | | 寻艳红 | 300.00 | 0.59 | -651.56 | | 贾君华 | 268.00 | 0.53 | 37.00 | | 宋益群 | 232.33 | 0.46 | 不变 | | 刘静芳 | 160.75 | 0.32 | 新进 | | 李明 | 159.88 | 0.31 | 新进 | | 邱琬书 | 155.22 | 0.31 | 新进 | | 罗文华 | 151.66 | 0.30 | -123.00 | | 较上个报告期退出前十大股东有 | | | | | 陈立云 | 266.40 | 0.5 ...

Business Focus and Strategy - The company reported a focus on eye care medical services, transitioning from steel structure and clean energy sectors[19]. - The company has not changed its major business since its listing, maintaining a focus on the medical and health industry[18]. - The company has undergone strategic adjustments through mergers and acquisitions to enhance its industry structure[19]. - The company aims to achieve over 90% coverage for annual eye health and vision checks for children aged 0-6 by 2025, with a target of reaching over 3,500 CSR nationwide[42]. - The company is focusing on enhancing the quality of ophthalmic medical services and implementing refined operational processes to improve efficiency[45]. - The company is actively promoting the transformation and upgrade of its cataract and refractive business, emphasizing high-end surgical techniques to meet patient demands[45]. - The company is committed to improving its medical quality management system and enhancing patient safety and service quality[46]. - The company is advancing digital transformation and smart hospital construction, optimizing operational efficiency and patient experience through technology[50]. - The company is expanding its network in key urban areas, forming a chain treatment system centered around five major city clusters[54]. - The company is committed to optimizing its investment strategy in the ophthalmology sector, with a focus on comprehensive development[175]. Financial Performance - The company's operating revenue for 2024 was ¥892,842,271.65, a decrease of 16.94% compared to ¥1,074,903,561.82 in 2023[20]. - The net profit attributable to shareholders for 2024 was -¥174,653,435.06, representing a significant decline of 1,987.12% from ¥9,255,045.17 in 2023[20]. - The cash flow from operating activities increased by 77.54% to ¥69,073,402.45 in 2024, compared to ¥38,905,978.76 in 2023[20]. - The total assets at the end of 2024 were ¥1,258,163,006.60, down 18.79% from ¥1,549,365,088.25 at the end of 2023[20]. - The net assets attributable to shareholders decreased by 60.21% to ¥112,700,100.63 at the end of 2024, compared to ¥283,257,684.81 at the end of 2023[20]. - The basic and diluted earnings per share for 2024 were both -¥0.34, a decline of 1,800.00% from ¥0.02 in 2023[20]. - The company achieved total operating revenue of 892.84 million yuan, a decrease of 16.94% compared to 1,074.90 million yuan in the previous year[44]. - Revenue from the medical sector was 778.30 million yuan, down 6.88% from 835.76 million yuan year-on-year, accounting for 87.17% of total revenue[44]. - Steel structure revenue fell to 79.19 million yuan, a significant drop of 61.78% from 207.19 million yuan year-on-year, representing 8.87% of total revenue[44]. - Energy sector revenue increased by 10.66% to 35.36 million yuan from 31.95 million yuan year-on-year, making up 3.96% of total revenue[44]. Market and Industry Trends - The company’s market for eye care is expected to continue expanding due to a large patient base and increasing demand driven by aging population and lifestyle factors[30]. - The refractive surgery market in China is expected to reach RMB 72.5 billion by 2025, growing from RMB 18.1 billion in 2019, with a CAGR of 32.3% from 2015 to 2019[32]. - The number of myopia patients in China is projected to increase from 533 million in 2019 to 618 million by 2025, with the overall myopia rate reaching 34.2%[32]. - The cataract patient population is expected to exceed 150 million by 2025, with the market size projected to reach RMB 33.9 billion[32]. - The medical optometry market in China is forecasted to grow from RMB 22.8 billion in 2019 to RMB 50.03 billion by 2025, with a CAGR of 14.6% from 2020 to 2025[33]. - The overall market for ocular surface disease treatment in China is anticipated to grow from RMB 9.4 billion in 2019 to RMB 21.9 billion by 2025, with a CAGR of 13.7%[34]. - The elderly population in China aged 60 and above has increased from 126 million in 2000 to 280 million in 2022, representing 19.8% of the total population[32]. - The government has implemented policies to encourage private medical institutions, enhancing the development environment for social healthcare providers[35]. - By 2030, the government aims to reduce the myopia rate among 6-year-olds to around 3% and among high school students to below 70%[33]. - The private medical market is expected to grow faster than the overall medical market, with a projected CAGR of 18% from 2020 to 2025[33]. Governance and Compliance - The governance structure has been strengthened to ensure compliance with regulatory requirements and enhance operational transparency[119]. - The board of directors consists of 9 members, including 3 independent directors, and held 8 meetings throughout the year[120]. - The supervisory board has 3 members, including 1 employee representative, and convened 7 meetings during the year[121]. - The company maintains independent operations in production, procurement, and sales, with no reliance on major shareholders or related parties[123]. - The company has established an independent financial department with a compliant financial accounting system, ensuring no interference from controlling shareholders[124]. - The company adheres to strict information disclosure practices, ensuring all shareholders receive equal access to relevant information[122]. - The company has established various committees under the board to provide professional opinions and references for decision-making[120]. - The company complies with all relevant regulations and has not faced penalties from regulatory bodies[135]. - The management team is committed to maintaining corporate governance standards and ensuring compliance with legal requirements[139]. Research and Development - The company has strengthened its academic and discipline construction, achieving significant results in research and collaboration with prestigious institutions[48]. - The company is developing new technologies to improve lens testing accuracy for high myopia patients, enhancing surgical outcomes[71]. - Ongoing research includes clinical applications of anti-VEGF drugs for diabetic retinopathy, aiming to reduce complications and improve patient quality of life[73]. - The company is collaborating with Fudan University to advance research in ophthalmology and develop innovative medical technologies[73]. - The number of R&D personnel decreased by 56.67% from 30 in 2023 to 13 in 2024, with the proportion of R&D personnel in total staff dropping from 1.78% to 0.81%[74]. - R&D expenditure fell by 27.89% from ¥4,965,402.61 in 2023 to ¥3,580,360.61 in 2024, representing 0.40% of operating revenue, down from 0.46%[74]. Talent Management - The company has a strong talent acquisition strategy, collaborating with universities to enhance its talent pool and training programs[57]. - The company has established a talent reserve mechanism combining internal training and external recruitment to mitigate the risk of talent loss[109]. - The company has implemented a competitive compensation system and a restricted stock incentive plan to enhance talent retention and motivation[59]. - The company has a total of 1,866,500 shares held by its senior management team, with individual holdings as follows: Yang Hongxin 0 shares, Zhou Helian 321,000 shares, Chen Zhifang 190,000 shares, Liu Lin 400,000 shares, Lian Jingcai 420,000 shares, and Rong Ao 435,500 shares[151][152][154][156][158]. - The company has a diverse management team with significant experience in various sectors, including finance and healthcare[138]. Shareholder Engagement - The annual shareholders' meeting had a participation rate of 26.57% on May 20, 2024, where several key proposals were approved, including the 2023 annual report[126]. - The company plans to implement a shareholder return plan for 2024-2026, which was approved in the annual shareholders' meeting[126]. - The company has a robust communication strategy with stakeholders, ensuring balanced interests among shareholders, employees, customers, and suppliers[121]. Future Outlook - For 2025, the company aims to achieve a sales revenue of 1,087.18 million yuan and a net profit of 38.12 million yuan, with a net profit attributable to the parent company of 35.89 million yuan[95]. - The core strategy focuses on "strengthening ophthalmology medical business and accelerating the integration of auxiliary industries," with an emphasis on lean management to improve operational quality[94]. - The company plans to enhance its business structure by promoting high-end cataract surgeries and refining its refractive surgery offerings to meet the increasing quality demands of patients[98]. - The company will strengthen academic construction and deepen collaboration with universities and research institutions to advance cutting-edge ophthalmology technologies[100]. - The company is set to grant a total of 3 million restricted stock units to eligible incentive targets on August 29, 2024[177].

光正眼科（002524）公告，2024年营业收入8.93亿元，同比下降16.94%。归属于上市公司股东的净亏损 1.75亿元，去年同期净利润925.5万元。基本每股收益-0.34元/股。公司计划不派发现金红利，不送红 股，不以公积金转增股本。 ...

内部控制审计报告 众环审字(2025) 0102102 号 光正眼科医院集团股份有限公司全体股东: 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求,我们审计了光 正眼科医院集团股份有限公司(以下简称"光正眼科公司")2024年12月31 日的财务报告 内部控制的有效性。 一、光正眼科公司对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业内部控制评价指引》 的规定,建立健全和有效实施内部控制,并评价其有效性是光正眼科公司董事会的责任。 二、注册会计师的责任 我们的责任是在实施审计工作的基础上,对财务报告内部控制的有效性发表审计意见, 并对注意到的非财务报告内部控制的重大缺陷进行披露。 三、内部控制的固有局限性 内部控制具有固有局限性,存在不能防止和发现错报的可能性。此外,由于情况的变化 可能导致内部控制变得不恰当,或对控制政策和程序遵循的程度降低,根据内部控制审计结 果推测未来内部控制的有效性具有一定风险。 四、财务报告内部控制审计意见 我们认为,光正限科医院集团股份有限公司于 2024年12月 31日按照《企业内部控制 基本规范》和相关规定在所有重大方面保持了有效 ...

传赢 Fax: 027-85424329 于光正眼科医院集团股份有限公司股份有限公 性资金占用及其他关联资金往来情况 的专项目核报告 众环专字(2025) 0100815 号 光正眼科医院集团股份有限公司全体股东: 我们接受委托,在审计了光正眼科医院集团股份有限公司(以下简称"光正眼科公司") 2024年 12月 31 日合并及公司的资产负债表,2024年度合并及公司的利润表、合并及公司 的现金流量表和合并及公司的股东权益变动表以及财务报表附注的基础上,对后附的《上市 公司 2024 年度非经营性资金占用及其他关联资金往来的情况汇总表》(以下简称"汇总表") 进行了专项审核。按照中国证券监督管理委员会印发的《上市公司监管指引第8号 -- 上市 公司资金往来、对外担保的监管要求》的规定,编制和披露汇总表、提供真实、合法、完整 的审核证据是光正眼科公司管理层的责任,我们的责任是在执行审核工作的基础上对汇总表 发表专项审核意见。 我们按照中国注册会计师审计准则的相关规定执行了审核工作。中国注册会计师审计准 则要求我们遵守中国注册会计师职业道德守则,计划和执行审核工作以对汇总表是否不存在 重大错报获取合理保证。在审核 ...

光正眼科医院集团股份有限公司 关于下属子公司综合授信及担保事项的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 截至本公告披露日，光正眼科医院集团股份有限公司（以下简称"公司"） 及控股子公司对外担保总额超过最近一期经审计净资产 100%，均为公司、控股 子公司、全资子公司及其下属公司间互相担保。敬请投资者关注担保风险。 光正眼科医院集团股份有限公司 证券代码：002524 证券简称：光正眼科 公告编号：2025-026 一、概述 公司于 2024 年 4 月 23 日召开第五届董事会第二十四次会议和第五届监事会 第十九次会议，分别审议通过了《关于公司、子公司及其下属公司 2024 年度向 银行等相关金融机构申请综合授信额度并提供担保的议案》，同意根据公司 2024 年度生产经营计划和发展规划，公司及控股子公司拟将向银行等相关金融机构申 请总额不超过 7 亿元的综合授信，公司、控股子公司及其下属公司间为上述综合 授信提供累计不超过 6.5 亿元(含)的担保额度，授信及担保额度的有效期自 2023 年度股东大会审议通过之日起 12 个月内有 ...

是否为 光正眼科医院集团股份有限公司 证券代码：002524 证券简称：光正眼科 公告编号：2025- 025 光正眼科医院集团股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、本次股份质押的基本情况 光正眼科医院集团股份有限公司（以下简称"公司"）近日收到控股股东光 正投资有限公司（以下简称"光正投资"）函告，获悉光正投资将所持有本公司 的部分股份办理了质押续期及补充质押的相关手续，具体情况如下： 形。 控股股 | | | | | | | 是否 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 东或第 | 本次 | | 占其所持 | 占公司 | 是否 | | | | | | | | | | | | | | | 为补 | | | | | | | | | | 一大股 | 质押续期 | | 股份 | 总股本 | 为限 | | | | | | 续期后 | | | | | | | | | 充质 ...

光正眼科医院集团股份有限公司 证券代码：002524 证券简称：光正眼科 公告编号：2025-025 光正眼科医院集团股份有限公司 关于控股股东部分股份质押续期的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 注：本次质押续期不涉及负担重大资产重组等业绩补偿义务。 1 光正眼科医院集团股份有限公司 2.控股股东股份累计质押的情况 截至公告披露日，公司控股股东及其一致行动人所持质押股份情况如下： | | | | | | | | | | 已质押股份 | | 未质押股份 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | 本次质押 | | | | | 情况 | | 情况 | | | 股东名称持股数量 | | 持股比例本次质押 | | 后质押股 | | | 占其所持 | 占公司股 | 已质押股 | | 未质押股 | | | | （股） | | 前质押股 | | | | 股 份比 | 本比例 | 份限售和 | | | 占未质 | ...

光正眼科医院集团股份有限公司 公司代行董事会秘书周永麟先生的联系方式如下： 办公电话：0991-3766551 电子邮箱：luoping@xsjyk.com 证券代码：002524 证券简称：光正眼科 公告编号：2025-024 光正眼科医院集团股份有限公司 关于公司董事会秘书辞职的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 光正眼科医院集团股份有限公司（以下简称"公司"）董事会近日收到董事 会秘书刘光波先生的辞职报告，刘光波先生因个人原因辞去公司董事会秘书职务， 辞职后刘光波先生将不在公司担任任何职务。 根据《公司法》、《深圳证券交易所股票上市规则》、《上市公司规范运作》 和《公司章程》等的相关规定，刘光波先生的辞职报告自送达公司董事会时生效。 公司未聘任新的董事会秘书期间，公司董事长周永麟先生将继续代为履行董事会 秘书职责，刘光波先生的辞职不会影响公司相关工作的正常进行；公司将按照相 关规定尽快聘请新的董事会秘书， 截至本公告披露日，刘光波先生未持有公司股份。公司及公司董事会对刘光 波先生在任职期间为公司发展所做的贡献表示衷心感谢。 通讯地址：新 ...